Genprex, Inc. Earnings Per Share (Basic)
Genprex, Inc. (GNPX) reported Earnings Per Share (Basic) of -$9.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- Genprex, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$9.40.
- Genprex, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.64.
- Genprex, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$1.80.
- Genprex, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$5.00.
- Genprex, Inc. earnings per share, basic for fiscal 2025 was -$17.40.
- Genprex, Inc. earnings per share, basic for fiscal 2024 was -$266.89.
- Genprex, Inc. earnings per share, basic for fiscal 2023 was -$22.56.
- Genprex, Inc. earnings per share, basic for fiscal 2022 was -$19.80.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.40 10-Q · filed 2026-08-14 | -$22.55 10-Q · filed 2026-08-14 | ||||||
| 2026-03-31 | -$0.64 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | -$1.80 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$5.29 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$12.71 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$17.40 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$5.00 10-Q · filed 2025-11-14 | -$21.57 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$23.00 10-Q · filed 2025-11-14 | -$53.00 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-06-30 | -$185.30 10-Q · filed 2026-08-14 | -$0.17 10-Q · filed 2025-08-14 | -$439.78 10-Q · filed 2026-08-14 | -$0.40 10-Q · filed 2025-08-14 | -$77.03 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$120.21 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2025-03-31 | -$12.98 10-Q · filed 2026-05-13 | -$0.26 10-Q · filed 2025-05-12 | -$34.57 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$68.79 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$28.18 derived: net income ÷ weighted average shares · filed 2026-05-13 | |||
| 2024-12-31 | -$24.80 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$70.69 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$18.88 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$266.89 10-K · filed 2026-03-30 | -$5.34 10-K · filed 2025-04-01 | |||
| 2024-09-30 | -$61.65 10-Q · filed 2025-11-14 | -$1.23 10-Q · filed 2024-11-13 | -$9.69 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$344.92 10-Q · filed 2025-11-14 | -$6.90 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$3.00 10-Q · filed 2025-08-14 | -$6.59 10-Q · filed 2025-08-14 | ||||||
| 2024-03-31 | -$3.86 10-Q · filed 2025-05-12 | -$3.69 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | -$22.56 10-K · filed 2025-04-01 | |||||||
| 2023-09-30 | -$5.36 10-Q · filed 2024-11-13 | -$0.13 10-Q · filed 2023-11-14 | -$18.77 10-Q · filed 2024-11-13 | -$0.47 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | -$6.14 10-Q · filed 2024-08-09 | -$0.15 10-Q · filed 2023-08-21 | -$13.55 10-Q · filed 2024-08-09 | -$0.34 10-Q · filed 2023-08-21 | ||||
| 2023-03-31 | -$7.44 10-Q · filed 2024-05-15 | -$0.19 10-Q · filed 2023-05-22 | ||||||
| 2022-12-31 | -$19.80 10-K · filed 2024-04-01 | -$0.50 10-K · filed 2023-03-31 | ||||||
| 2022-09-30 | -$0.13 10-Q · filed 2023-11-14 | -$0.36 10-Q · filed 2023-11-14 | -$0.35 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | -$0.12 10-Q · filed 2023-08-21 | -$0.11 10-Q · filed 2022-08-12 | -$0.23 10-Q · filed 2023-08-21 | |||||
| 2022-03-31 | -$0.11 10-Q · filed 2023-05-22 | -$0.12 10-Q · filed 2022-05-13 | ||||||
| 2021-12-31 | -$0.44 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | -$0.07 10-Q · filed 2022-11-14 | -$0.30 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$0.08 10-Q · filed 2022-08-12 | -$0.23 10-Q · filed 2022-08-12 | ||||||
| 2021-03-31 | -$0.11 10-K · filed 2023-03-31 | -$0.14 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |